about
Mechanism of thioamide drug action against tuberculosis and leprosyIdentification of a type III thioesterase reveals the function of an operon crucial for Mtb virulenceTriclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-ResistantMycobacterium tuberculosisGenetic Incorporation of a Metal-Ion Chelating Amino Acid into Proteins as a Biophysical ProbeGenetic incorporation of unnatural amino acids into proteins in Mycobacterium tuberculosisCrystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibioticsAuranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasisA new strategy to photoactivate green fluorescent protein.Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.Functional antibody CDR3 fusion proteins with enhanced pharmacological properties.An antibody CDR3-erythropoietin fusion proteinRational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones.Homogeneously modified immunoglobulin domains for therapeutic application.Rational design of CXCR4 specific antibodies with elongated CDRs.Stabilizing Protein Motifs with a Genetically Encoded Metal-Ion Chelator.Rational design of antibody protease inhibitors.Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.Mutational analysis of 48G7 reveals that somatic hypermutation affects both antibody stability and binding affinityMycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.An immunosuppressive antibody-drug conjugate.Antibody-drug conjugates for non-oncological indications.Multifunctional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide Receptors.Rational design of humanized dual-agonist antibodies.Genetically encoding phosphotyrosine and its nonhydrolyzable analog in bacteria.Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.Engineering Bifunctional Antibodies with Constant Region Fusion Architectures.Biochemical characterization of enoyl reductase involved in Type II fatty acid synthesis in the intestinal coccidium Eimeria tenella (Phylum Apicomplexa).Retraction of "Mutational Analysis of 48G7 Reveals that Somatic Hypermutation Affects Both Antibody Stability and Binding Affinity".Small molecules targeting Mycobacterium tuberculosis type II NADH dehydrogenase with antimycobacterial activity.Unnatural amino acid mutagenesis of fluorescent proteins.Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.Functional Replacement of Histidine in Proteins To Generate Noncanonical Amino Acid Dependent Organisms.Reshaping Antibody DiversityNatural product inhibitors of fatty acid biosynthesis: synthesis of the marine microbial metabolites pseudopyronines A and B and evaluation of their anti-infective activitiesSmall Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial ActivityDeterminants of the Inhibition of DprE1 and CYP2C9 by Antitubercular ThiophenesAn Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody ScaffoldAn Antibody with a Variable-Region Coiled-Coil “Knob” DomainA New Strategy to Photoactivate Green Fluorescent Protein
P50
Q24676495-5CFCE010-1CB4-45DD-9AC8-95E870714CFBQ27644924-5808223E-7FC3-48C3-BF56-9294B320B94BQ27653366-B0CB7299-D843-43DB-8255-F6AB7850F9C0Q27653644-12257D47-2635-4911-82FF-7A4E48A33A0EQ28472988-BE795ACB-1A85-4CB5-815A-1E2D956D05BAQ28487411-EF7C52C4-8E46-4133-84D9-7F5E2A399341Q29013419-8FD50C06-B279-4833-8D9F-3B5D7FCFB259Q34192229-92266915-83F6-4FBA-8F60-3D362779575CQ35062566-58B2AE2B-C338-4B0A-8C7C-8A560962B676Q37197904-D983DB40-3BA8-4248-B3FF-4BB97330520CQ37239377-AE468E4A-7296-4D4F-A825-9C8299B7F825Q37346963-79E4FAB3-0CBD-412C-91D2-2C466EB4CDFEQ37490723-0E19B992-5848-44D7-9902-6F6B3C55EF85Q38539192-35F41223-095E-4A99-8998-05C5178FB869Q38973911-51283828-64F4-41DE-BEB8-BB26D43511CEQ40568405-59EE03A5-8905-4E81-9748-665FD2820F0EQ41210975-0453F913-9BA0-480B-BB25-45C2C612E99EQ41629204-D8BE5FB8-3D46-4F87-87E1-75F07ADAE0F6Q41768898-3566BF05-8186-4C3A-9445-2867FF970AEAQ41845349-95CBE9F8-6E26-41A6-9EBC-CC8FEB3176B7Q42207099-5AEB8C77-9FB5-4E46-B1D1-651AF0B1C5ABQ46036446-42141DA9-BD0E-4D39-978F-E738DA1ED05FQ46063056-F645714D-2393-40AF-BF57-E3AAF246E440Q46084725-938EC983-18AC-40AD-B686-72A962E9D736Q46198324-830AC481-1530-4D36-84AD-6F577977E1C1Q46272152-35569EBA-6A3E-487C-81FA-1B680CDEB8AEQ46674470-0A4FAAA5-57AE-48D8-9ACE-49309AAFCB29Q48078902-36146656-C00C-4DDA-B28A-908A36C1EBBDQ48152934-E3549CD8-05BB-48AD-B7B2-99C334313D3EQ49503368-1A5CA1E8-BB32-412C-8A11-177FC03C758AQ50491182-FE931A2F-FB13-49B2-A2A2-5C44CA66FAFAQ53590893-1BA67012-E98A-4416-BB63-B8E29A94F527Q54208620-BD2503B6-E07F-4B19-89C2-C68CCE6168A9Q57170098-64F0E197-BA06-4C23-B277-B80AF1AC1440Q58848600-072F209D-C28B-451C-BCA1-2C82FE62CE7BQ63363108-5A7E19F0-7174-4D6D-BAA7-9C3B0566C1D1Q63363109-3860371D-4CBF-413C-B927-27AEA79767E3Q63363110-4B2114F4-B134-48F1-9603-01F090477FB0Q63363111-DFACC18A-6DD2-4632-B1B4-E61A87F34612Q63363112-402AC5CC-5ACE-4B1A-BD03-19BDBE107FEF
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0003-2980-4646
@en
name
Feng Wang
@ast
Feng Wang
@en
Feng Wang
@es
Feng Wang
@sl
type
label
Feng Wang
@ast
Feng Wang
@en
Feng Wang
@es
Feng Wang
@sl
prefLabel
Feng Wang
@ast
Feng Wang
@en
Feng Wang
@es
Feng Wang
@sl
P108
P106
P108
P21
P31
P496
0000-0003-2980-4646